natgillin/translations-raw huggingface dataset:
The dsRNA for use of claim 14 or 15, wherein the human is additionally receiving a therapeutic method for treating a TTR amyloidosis, the therapeutic method selected from the group consisting of diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, dialysis, and a liver transplant. 
dsRNA za uporabu prema zahtjevu 13 ili 14, naznačena time da čovjek dodatno prima terapijski postupak za liječenje TTR amiloidoze, te je terapijski postupak odabran iz skupine koja sadrži diuretike, inhibitore angiotenzin pretvarajućeg enzima, blokatore receptora angiotenzina, dijalizu, ili transplantaciju jetre.
Container according to claim 1, characterized in that the cross beams (12,13) are flat, with vertical transverse edges, wherein the upper longitudinal edge of the upper cross beams (13) is flush with the top end section of the stiles (11). 
Spremnik sukladno Zahtjevu 1, naznačen time što su poprečne grede (12, 13) plosnate, s vertikalnim transverzalnim rubovima, pri čemu je gornji longitudinalni rub gornjih poprečnih greda (13) u ravnini s gornjim dijelom dijelova na ogradi (11).
Container according to claim 3, characterized in that the inside of the corner support legs (4) has a diagonal dividing wall (7) delimiting a triangular-section external housing (8) for mounting the stiles (11). 
Spremnik sukladno Zahtjevu 3, naznačen time što unutrašnjost kutnih potpornih nogu (4) ima dijagonalni zid (7) koji ograničava trokutasti dio vanjskog kućišta (8) za pričvršćivanje dijelova na ogradi (11).
Container according to any of the preceding claims, characterized in that the side cover (3) is tightly mounted around the stiles (11), and reinforced with peripheral tightening straps. 
Spremnik sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što je bočni pokrov (3) tijesno pričvršćen oko dijelova na ogradi (11), te pojačan perifernim zateznim trakama.
Container according to any of the preceding claims, characterized in that the side cover (3) has a folded flap along its lower perimeter for keeping said cover from sliding below the intended level and for ensuring greater rigidity and preventing it from being deformed. 
Spremnik sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što bočni pokrov (3) ima presavijeni preklop duž donjeg ruba kako bi spriječio klizanje navedenog pokrova ispod određene razine i za osiguravanje čvrstoće i sprečavanje deformacija.
Container according to any of the preceding claims, characterized in that the side cover (3) has, at least on one of its sides, and starting from the top edge of the same, a central area delimited by a perforated or tear line (14), which when torn forms a window (15) through which the product (16) contained within is visible. 
Spremnik sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što bočni pokrov (3) ima, barem na jednoj od strana, te počevši od gornjeg ruba istog, središnje područje ograničeno perforiranom ili linijom reza (14), kidanjem koje se oblikuje prozor (15) kroz koji je vidljiv proizvod (16) u unutrašnjosti.
Container according to any of the preceding claims, characterized in that the platform (1) is made of a plastic material and has multiple openings to enable the ventilation of the product housed inside the container. 
Spremnik sukladno bilo kojem od prethodnih Zahtjeva, naznačen time što je platforma (1) načinjena od plastičnog materijala i ima više otvora kako bi se omogućila ventilacija proizvoda unutar spremnika.
The radiator element according to Claim 7, wherein the plug (20) is made of aluminium and the fixing member (38) is made of sheet metal, for example steel. 
Element radijatora u skladu s patentnim zahtjevom 7, naznačen time, da je čep (20) napravljen od aluminija i pričvrsni element (38} da je izrađen od lima, na primjer čelika.
A device (50) for closing an end part of a heating radiator element, in particular by mounting a plug on the end part of the radiator element, comprising: 
Uređaj (50) za zatvaranje krajnjeg dijela elementa za grijanje radijatora, posebice ugradnja čepa na krajnjem dijelu elementa radijatora, koji sadrži:
The device according to Claim 12, wherein the clamping group (51) is shaped so as to clamp the assembly (53) housed in the seat (52) laterally on opposite sides. 
Uređaj u skladu s patentnim zahtjevom 12, naznačen time, da je skupina steznih elemenata (51) oblikovana na način da povezuje sklop (53) koji je smješten na nosaču (52), bočno na suprotnim stranama.
The device according to Claim 14, comprising a detent (59) co-operating with the half-grippers (57) to stop the movement of the half-grippers (57) in a preset position in the sliding direction (S). 
Uređaj u skladu s patentnim zahtjevom 14, naznačen time, da sadrži jedan osigurač (59) koji u suradnji sa polu-hvataljkama (57) omogućuju zaustavljanje polu-hvataljki (57) u prilagodljiv položaj u kliznom smjeru (S).
is CH3; for use in treating a subject suffering from or susceptible to a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
je CH3, za uporabu u liječenju subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
the compound or pharmaceutically acceptable salt thereof of any of the preceding claims, for use in treating a subject suffering from or susceptible to a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer; and 
tvar ili njenu farmaceutski prihvatljivu sol iz bilo kojeg od prethodnih patentnih zahtjeva, za uporabu u liječenju subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom;
an acceptable carrier. 
i prihvatljivi nosač.
A compound, pharmaceutically acceptable salt thereof or composition according to claim 4, for use in treatment of neuropathic pain or pseudobulbar affect. 
Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 4, za uporabu u liječenju neuropatske boli ili pseudobulbarnog afekta.
A compound, pharmaceutically acceptable salt thereof or composition according to claim 5, for use in treatment of pseudobulbar affect. 
Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 5, za uporabu u liječenju pseudobulbarnog afekta.
The composition of any of claims 3-6, further comprising a second therapeutic agent useful in the treatment or prevention of a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; retinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine; chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
Sastav u skladu s bilo kojim od patentnih zahtjeva 3-6, nadalje obuhvaća drugi terapijski agens koristan u liječenju ili sprečavanju bolesti ili stanja odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
The composition, separate dosage form or package according to any of claims 7-13, for use in treating a subject suffering from or susceptible to diabetic neuropathy, wherein the second agent is quinidine sulfate. 
Sastav, zasebni oblici doziranja ili pakiranje u skladu s bilo kojim od patentnih zahtjeva 7-13, za uporabu u liječenju subjekta subjekta koji pati od ili je podložan dijabetičkoj neuropatiji, pri čemu je drugi agens kinidin sulfat.
is CH3; in the manufacture of a medicament for the treatment of a subject suffering from or susceptible to a disease or condition selected from emotional lability; pseudobulbar affect; autism; neurological disorders; neurodegenerative diseases; brain injury; disturbances of consciousness disorders; cardiovascular diseases; glaucoma; tardive dyskinesia; diabetic neuropathy; rotinopathic diseases; diseases or disorders caused by homocysteine-induced apoptosis; diseases or disorders caused by elevated levels of homocysteine: chronic pain; intractable pain; neuropathic pain; sympathetically mediated pain; pain associated with gastrointestinal dysfunction; epileptic seizures; tinnitus; sexual dysfunction; intractable coughing; dermatitis; addiction disorders; Rett syndrome (RTT); voice disorders due to uncontrolled laryngeal muscle spasms; methotrexate neurotoxicity; and fatigue caused by cancer. 
je CH3, za uporabu u proizvodnji lijeka za liječenje subjekta koji pati od ili je podložan bolesti ili stanju odabranih između emocionalne labilnosti; pseudobulbarnog afekta; autizma; neuroloških poremećaja; neurodegenerativnih bolesti; ozljeda mozga; poremećaja narušavanja svijesti; kardiovaskularnih bolesti; glaukoma; tardivne diskinezije; dijabetičke neuropatije; retinopatskih bolesti; bolesti ili poremećaja uzrokovanih homocisteinom induciranom apoptozom; bolesti ili poremećaja uzrokovanih povećanom razinom homocisteina; kronične boli; tvrdokorne boli; neuropatske boli; simpatički posredovane boli; boli povezane s gastrointestinalnom disfunkcijom; epileptičkih napada; tinitusa; seksualne disfunkcije; tvrdokornog kašlja; dermatitisa; poremećaja ovisnosti; Rett sindroma (RTT); poremećaja glasa zbog nekontroliranog spazma mišića larinksa; neurotoksičnosti metotreksata; i umora uzrokovanog karcinomom.
Apparatus according to claim 1 characterized in that said means for keeping the outside of said shielding means (6) at a temperature above the dew point comprise a thermal insulation and/or heating means (312), in particular electric heating means. 
Uređaj prema patentnom zahtjevu 1 naznačen time da navedena sredstva za održavanje vanjskog dijela navedenih zaštitnih sredstava (6) na temperaturi iznad točke rosišta sadrže toplinsku izolaciju i/ili sredstva za grijanje (312), naročito električna sredstva za grijanje.
Apparatus according to any of claims 1 to 6 characterized in that said delivery nozzle (4) is in fluid communication with a source of a cryogenic fluid, especially liquid nitrogen. 
Uređaj prema bilo kojem zahtjevu 1 do 6 naznačen time da je navedena mlaznica za dostavu (4) u fluidnoj komunikaciji s izvorom kriogenog fluida, naročito tekućeg dušika.
Method according to claim 9 characterized in that said outside of said shielding means (6) is heated by heating means (312), especially by an electric heater. 
Postupak prema patentnom zahtjevu 9 naznačen time da se navedeni vanjski dio navedenih zaštitnih sredstava (6) zagrijava pomoću sredstava za grijanje (312), naročito pomoću električnog grijača.
Method according to any of claims 9 to 12 characterized in that a cryogenic fluid, in particular liquid nitrogen, is used as coolant (2). 
Postupak prema bilo kojem od zahtjeva 9 do 12 naznačen time da se kao rashladno sredstvo (2) koristi kriogeni fluid, naročito tekući dušik.
Method according to any of claim 9 to 14 characterized in that the pressure within the essentially closed space is controlled by adjusting the flow of coolant (2) sprayed and / or by adjusting the flow of gas withdrawn from the essentially closed space. 
Postupak prema bilo kojem zahtjevu 9 do 14 naznačen time da se tlak unutar uglavnom zatvorenog prostora kontrolira podešavanjem protoka rashladnog sredstva (2) raspršivanjem i/ili podešavanjem protoka plinovitog rashladnog sredstva koje se izvlači iz uglavnom zatvorenog prostora.
Ar5', where Ar5' is a 5-membered monocyclic heteroaryl having carbon as a point of attachment, with one heteroatom selected from the group consisting of O, S, >NH, and >NRf, wherein Rf is -C1-8alkyl or -C0-3phenalkyl, and having zero, one, two, or three additional nitrogen heteroatoms, and 
Ar5’, gdje je Ar5’ petočlani monociklički heteroaril koji ima ugljik kao točku spajanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od: O, S, >NH, i >NRf, gdje je Rf -C1-8alkil ili -C0-3fenalkil, i ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i
or a pharmaceutically acceptable salt of such compound. 
ili farmaceutsko prihvatljive soli takvog spoja.
a 9- or 10-membered fused bicyclic heteroaryl having one heteroatom selected from the group consisting of N, O, and S, with a carbon atom as point of ring attachment, and optionally having up to four additional carbon ring atoms replaced with nitrogen, said fused bicyclic heteroaryl having not more than five heteroatoms, and unsubstituted or substituted with one, two, or three Re substituents as previously defined; 
devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom vezanja prstena, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenuti fuzionirani biciklični heteroaril koji nema više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano;
phenyl substituted at the 3- or 4-position with -L-Ar3, wherein: 
fenil supstituiran na trećoj ili četvrtoj poziciji sa -1-Ar3, gdje:
A compound as defined in claim 1 selected from the group consisting of: 
Spoj kao što je definirano prema patentnom zahtjevu 1 naznačen time da je izabran iz grupe koja se sastoji od:
a 9- or 10-membered fused bicyclic heteroaryl having one heteroatom selected from the group consisting of N, O, and S, with a carbon atom as point of ring attachment, and optionally having up to four additional carbon ring atoms replaced with nitrogen, said fused bicyclic heteroaryl having not more than five heteroatoms, and unsubstituted or substituted with one, two, or three Re substituents as previously defined; 
devetočlani ili desetočlani fuzionirani biciklični heteroaril koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa atomom ugljika kao točkom prstenastog vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od pet heteroatoma, i nesupstituiran ili supstituiran sa jednim, dva, ili tri Re supstituenta kao što je prethodno definirano;
or a pharmaceutically acceptable salt of such compound for use in treating a disease, disorder or medical condition mediated by FAAH activity. 
ili farmaceutski prihvatljive soli takvog spoja za primjenu u liječenju bolesti, poremećaja ili medicinskih stanja posredovanih FAAH aktivnošću.
A compound according to claim 25, wherein said compound is selected from the group consisting of: 
Spoj prema patentnom zahtjevu 25, naznačen time da je spomenuti spoj izabran iz grupe koja se sastoji od:
and pharmaceutically acceptable salts thereof. 
i farmaceutsko prihvatljive soli istih.
A compound according to claim 11, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, sleep disorders, eating disorders, inflammation, movement disorders, HIV wasting syndrome, closed head injury, stroke, Alzheimer's disease, epilepsy, Tourette's syndrome, Niemann-Pick disease, Parkinson's disease, Huntington's chorea, optic neuritis, autoimmune uveitis, drug withdrawal, nausea, emesis, sexual dysfunction, post-traumatic stress disorder, cerebral vasospasm, glaucoma, irritable bowel syndrome, inflammatory bowel disease, immunosuppression, gastroesophageal reflux disease, paralytic ileus, secretory diarrhea, gastric ulcer, rheumatoid arthritis, unwanted pregnancy, hypertension, cancer, hepatitis, allergic airway disease, autoimmune diabetes, intractable pruritis, and neuroinflammation. 
Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje izabrano iz grupe koja se sastoji od: anksioznost, bol, poremećaji spavanja, poremećaji ishrane, inflamacija, poremećaji kretanja, sindrom HIV propadanja, povreda glave, šlog, Alzheimerova bolest, epilepsija, Touretteov sindrom, Niemann-Pikova bolest, Parkinsonova bolest, Huntingtonova horea, optički neuritis, autoimuni uveitis, apstinentska kriza, mučnina, povraćanje, seksualna disfunkcija, post traumatski stresni poremećaj, cerebralni vazospazam, glaukom, sindrom nadraženih crijeva, inflamatorna bolest crijeva, imunosupresija, gastroezofagusna refluksna bolest, paralitički ileus, sekretorna dijareja, čir na želucu, reumatoidni artritis, neželjena trudnoća, hipertenzija, karcinom, hepatitis, alergijska bolest disajnih puteva, autoimuni dijabetes, intraktabilni pruritis, i neuroinflamacija.
A compound according to claim 11, wherein the disease, disorder, or medical condition is selected from the group consisting of: anxiety, pain, inflammation, sleep disorders, eating disorders, and movement disorders. 
Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje izabrani iz grupe koja se sastoji od: anksioznost, bol, inflamacija, poremećaji spavanja, poremećaji ishrane, i poremećaji kretanja.
A compound according to claim 25, wherein the disease, disorder, or medical condition is multiple sclerosis. 
Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj, ili medicinsko stanje multipla skleroza.
A compound according to claim 25, wherein the disease, disorder, or medical condition is pain in inflammation. 
Spoj prema patentnom zahtjevu 25, naznačen time da su bolest, poremećaj ili medicinsko stanje bol kod inflamacije.
A pharmaceutical composition for treating a disease, disorder, or medical condition mediated by FAAH activity, comprising: 
Farmaceutski pripravak pri liječenju bolesti, poremećaja, ili medicinskog stanja posredovanog FAAH aktivnošću, naznačen time da sadrži:
an effective amount of an agent selected from the group consisting of compounds of Formula (I): wherein: 
efektivnu količinu agensa izabranog iz grupe koja se sastoji od spoja Formule (I):
phenyl substituted at the 3- or 4-position with -L-Ar3, wherein: 
fenil supstituiran na trećoj i četvrtoj poziciji sa -1-Ar3, gdje:
Ar5', where Ar5' is a 5-membered monocyclic heteroaryl having carbon as a point of attachment, with one heteroatom selected from the group consisting of O, S, >NH, and >NRf, wherein Rf is -C1-8alkyl or -C0-3phenalkyl, and having zero, one, two, or three additional nitrogen heteroatoms, and 
Ar5’, gdje Ar5’ je petočlani monociklički heteroaril koji ima ugljik kao točku vezanja, sa jednim heteroatomom izabranim iz grupe koja se sastoji od O, S, >NH, i >NRf, gdje Rf je -C1-8alkil ili -C0-3fenalkil, i ima nula, jedan, dva, ili tri dodatna heteroatoma dušika, i
and pharmaceutically acceptable salts thereof; and 
i farmaceutsko prihvatljivih soli istih; i
A pharmaceutical composition according to claim 31, wherein said agent is selected from the group consisting of: 
Farmaceutski pripravak prema patentnom zahtjevu 31, naznačen time da je spomenuti agens izabran iz grupe koja se sastoji od:
A fluid ejection device comprising a nozzle group, the nozzle group comprising a plurality of nozzle circuits (34) and a fire controller (56) in electronic communication with the plurality of nozzle circuits (34) and wherein: 
Skupina mlaznica za uređaj za izbacivanje fluida, koji se sastoji od više mlazničnih krugova (34) i regulatora okidanja (56) u elektronskoj komunikaciji s više mlazničnih krugova (34), te gdje:
The fluid ejection device of Claim 1, wherein each nozzle circuit includes a switching element and the firing element is configured to heat a fluid in a vaporization chamber (30) adjacent to a nozzle (22), the switching and firing elements (36, 26) are configured such that: 
Skupina mlaznica u skladu s patentnim zahtjevom 12, naznačena time što svaki mlaznični krug sadrži prekidni element, gdje je okidni element tako konfiguriran da zagrije fluid u komori za isparavanje (30) koja se nalazi uz mlaznicu (22), gdje su prekidni i okidni element (36, 26) tako konfigurirani da:
the fire controller (56) is operable to conditionally modify the firing signal according to a state of warm data received via the warm data input (62) and a state of fire data received via the fire data input (64); and 
regulator okidanja (56) tako radi da uvjetno modificira okidni signal ovisno o stanju podataka o grijanju primljeni kroz ulaz za podatke o grijanju (62) i stanju podataka o okidanju primljenih kroz ulaz za podatke o okidanju (64);